BR0014351A - Formulação e processo de antagonista de vasopressina - Google Patents

Formulação e processo de antagonista de vasopressina

Info

Publication number
BR0014351A
BR0014351A BR0014351-0A BR0014351A BR0014351A BR 0014351 A BR0014351 A BR 0014351A BR 0014351 A BR0014351 A BR 0014351A BR 0014351 A BR0014351 A BR 0014351A
Authority
BR
Brazil
Prior art keywords
formulation
component
vasopressin antagonist
pharmaceutically acceptable
formulations
Prior art date
Application number
BR0014351-0A
Other languages
English (en)
Inventor
Joseph Kyuwung Yoon
Richard William Saunders
Mahdi Bakir Fawzi
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of BR0014351A publication Critical patent/BR0014351A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçãO E PROCESSO DE ANTAGONISTA DE VASOPRESSINA". A invenção providencia novas formulações de N-[4-(5H-pirrol[2,1-c][1,4]benzodiazepin-10(11H)ilcarboni[)-3-clorofe nil]-5-flúor--2-metilbenzamida ou um sal farmaceuticamente aceitável deste, e processos para sua produção, compreendendo as formulações de cerca de 1 % a cerca de 20% do ingrediente ativo, de cerca de 1% a cerca de 18% de um componente tensoativo, de cerca de 50% a cerca de 80% de um componente de um ou mais polietilenoglicóis, de cerca de 1% a cerca de 20% de um componente de um ou mais ésteres de ácido graxo de sacarose, e/ou polivinilpirrolidona e, opcionalmente, um ou mais conservantes ou antioxidantes farmaceuticamente aceitáveis.
BR0014351-0A 1999-09-27 2000-09-26 Formulação e processo de antagonista de vasopressina BR0014351A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40577299A 1999-09-27 1999-09-27
PCT/US2000/026369 WO2001022945A1 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process

Publications (1)

Publication Number Publication Date
BR0014351A true BR0014351A (pt) 2002-06-11

Family

ID=23605168

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014351-0A BR0014351A (pt) 1999-09-27 2000-09-26 Formulação e processo de antagonista de vasopressina

Country Status (18)

Country Link
EP (1) EP1216033A1 (pt)
JP (1) JP2003510269A (pt)
KR (1) KR20020039354A (pt)
CN (1) CN1391466A (pt)
AR (1) AR025780A1 (pt)
AU (1) AU7615000A (pt)
BR (1) BR0014351A (pt)
CA (1) CA2388474A1 (pt)
CZ (1) CZ20021083A3 (pt)
EA (1) EA200200414A1 (pt)
HK (1) HK1045109A1 (pt)
HU (1) HUP0202972A3 (pt)
IL (1) IL148541A0 (pt)
MX (1) MXPA02003189A (pt)
NO (1) NO20021475L (pt)
PL (1) PL354282A1 (pt)
WO (1) WO2001022945A1 (pt)
ZA (1) ZA200203312B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
AU2003211267A1 (en) * 2002-02-27 2003-09-09 Shionogi And Co., Ltd. Solid preparations with improved absorbability of hardly water-soluble drug
JP5873375B2 (ja) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 ソフトカプセル及びソフトカプセルの製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
CA2318128C (en) * 1998-01-20 2008-10-14 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
CZ20021083A3 (cs) 2002-06-12
KR20020039354A (ko) 2002-05-25
CN1391466A (zh) 2003-01-15
NO20021475D0 (no) 2002-03-25
AR025780A1 (es) 2002-12-11
AU7615000A (en) 2001-04-30
IL148541A0 (en) 2002-09-12
HUP0202972A3 (en) 2003-07-28
EA200200414A1 (ru) 2002-12-26
CA2388474A1 (en) 2001-04-05
NO20021475L (no) 2002-04-16
HK1045109A1 (zh) 2002-11-15
MXPA02003189A (es) 2002-09-30
WO2001022945A1 (en) 2001-04-05
JP2003510269A (ja) 2003-03-18
PL354282A1 (en) 2003-12-29
HUP0202972A2 (hu) 2002-12-28
ZA200203312B (en) 2003-12-31
EP1216033A1 (en) 2002-06-26

Similar Documents

Publication Publication Date Title
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
WO1999033792A3 (en) Prodrugs os aspartyl protease inhibitors
RU95101048A (ru) Производные пролинамида, фармкомпозиция на их основе
MY129350A (en) Aripiprazole oral solution
MA26901A1 (fr) Nouvelle composition pharmaceutique
PT97638A (pt) Processo para a preparacao de compostos peptidicos e de composicoes farmaceuticas que os contem
BR9503386A (pt) Formulaçao farmacêutica comprimido dispersivel e processo para a fabricaçao de comprimidos dispersíveis contendo cloridrato de fluoxetina
DE50012571D1 (de) Biotin enthaltende galenische formulierung
YU78302A (sh) Derivat piridin-1-oksida i postupak za njegovu transformaciju u farmaceutski efikasna jedinjenja
WO2004087167A3 (en) Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
ATE253359T1 (de) Antithrombotische mittel
BR0014351A (pt) Formulação e processo de antagonista de vasopressina
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
EA199900226A1 (ru) Фармацевтические композиции для лечения вирусных заболеваний
ATE286395T1 (de) Antithrombotische mittel
WO2001022969A3 (en) Vasopressin agonist formulation and process
WO2000067732A3 (de) Pharmazeutische zusammensetzung enthaltend antimykotikum, polydocanol und salycylsaüre
IT1318424B1 (it) Composti con attivita' anti-hiv.
NO20032035L (no) Terapeutiske midler for keratokonjuktivitis sykdommer omfattende farnesyleddiksyre som aktiv ingrediens
ATE331509T1 (de) Zusammensetzung die paracetamol und niflumic säure enthält
AU1434201A (en) Antithrombotic agents
HUP0204150A2 (hu) A cisz-lítium-4-ciano-4-[3-(ciklopentil-oxi)-4-metoxi-fenil]-ciklohexánkarboxilát monohidrátja, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmény
DE69824410D1 (en) Antithrombosemittel
UA30143C2 (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
MX9605633A (es) Composicion farmaceutica, metodo y dispositivo para prevenir o tratar resequedad de los ojos o enfermedad ocasionada por la misma.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]